A preclinical study in Gene Therapy reported that gene augmentation therapy reversed complete congenital stationary night blindness in mice, restoring more reliable visual responses. The work targeted cCSNB, a genetic retinal disorder in which retinal circuitry fails to generate dependable signals from birth. Investigators reported improvements at the retinal level in mouse models, supporting continued translation of the approach toward further preclinical validation and eventual clinical development. While the study is not yet human data, it adds another gene-therapy candidate in inherited retinal disease. The results reinforce the feasibility of restoring function in severe early-onset ophthalmic genetic conditions.